TNSN00111A1 - Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN00111A1
TNSN00111A1 TNTNSN00111A TNSN00111A TNSN00111A1 TN SN00111 A1 TNSN00111 A1 TN SN00111A1 TN TNSN00111 A TNTNSN00111 A TN TNSN00111A TN SN00111 A TNSN00111 A TN SN00111A TN SN00111 A1 TNSN00111 A1 TN SN00111A1
Authority
TN
Tunisia
Prior art keywords
tetrahydropyranne
carboxyliques
arylsulfonylamino
preparation
pharmaceutical compositions
Prior art date
Application number
TNTNSN00111A
Other languages
English (en)
Inventor
Alan Reiter Lawrance
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00111A1 publication Critical patent/TNSN00111A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Abstract

L’INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1, R2, R3, R4, ET Q REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS D’ENZYMES, POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN00111A 1999-05-28 2000-05-24 Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN00111A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13653099P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
TNSN00111A1 true TNSN00111A1 (fr) 2002-05-30

Family

ID=22473239

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00111A TNSN00111A1 (fr) 1999-05-28 2000-05-24 Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (22)

Country Link
US (1) US6197810B1 (fr)
EP (1) EP1181286B1 (fr)
JP (1) JP3784645B2 (fr)
AT (1) ATE254119T1 (fr)
AU (1) AU4424000A (fr)
BR (1) BR0011539A (fr)
CA (1) CA2375524C (fr)
DE (1) DE60006523T2 (fr)
DK (1) DK1181286T3 (fr)
DZ (1) DZ3046A1 (fr)
ES (1) ES2208315T3 (fr)
GT (1) GT200000079A (fr)
HN (1) HN2000000074A (fr)
MA (1) MA26738A1 (fr)
MX (1) MXPA01012265A (fr)
PA (1) PA8495901A1 (fr)
PE (1) PE20010170A1 (fr)
PT (1) PT1181286E (fr)
SV (1) SV2001000086A (fr)
TN (1) TNSN00111A1 (fr)
UY (1) UY26167A1 (fr)
WO (1) WO2000073295A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2001070693A2 (fr) 2000-03-21 2001-09-27 The Procter & Gamble Company Inhibiteurs de metalloproteases d'acide difluorobutyrique
PL357250A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
CA2404131A1 (fr) 2000-03-21 2001-09-27 The Procter & Gamble Company Inhibiteurs de metalloproteases n-substitues renfermant une chaine laterale heterocyclique
US7019376B2 (en) * 2000-08-11 2006-03-28 Reflectivity, Inc Micromirror array device with a small pitch size
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
PL2385938T3 (pl) 2009-01-12 2015-07-31 Pfizer Ltd Pochodne sulfonamidu
CA2804173C (fr) 2010-07-09 2015-01-13 Pfizer Limited Inhibiteurs de nav1.7 de type sulfonamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL131042A (en) 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico

Also Published As

Publication number Publication date
CA2375524A1 (fr) 2000-12-07
ATE254119T1 (de) 2003-11-15
AU4424000A (en) 2000-12-18
SV2001000086A (es) 2001-11-08
DK1181286T3 (da) 2004-02-16
JP3784645B2 (ja) 2006-06-14
MXPA01012265A (es) 2002-07-30
CA2375524C (fr) 2006-11-28
PE20010170A1 (es) 2001-02-27
JP2003500485A (ja) 2003-01-07
EP1181286B1 (fr) 2003-11-12
WO2000073295A1 (fr) 2000-12-07
DE60006523D1 (de) 2003-12-18
BR0011539A (pt) 2002-02-26
HN2000000074A (es) 2001-02-02
UY26167A1 (es) 2000-12-29
MA26738A1 (fr) 2004-12-20
GT200000079A (es) 2001-11-16
DE60006523T2 (de) 2004-08-12
ES2208315T3 (es) 2004-06-16
US6197810B1 (en) 2001-03-06
EP1181286A1 (fr) 2002-02-27
PA8495901A1 (es) 2002-08-26
DZ3046A1 (fr) 2004-03-27
PT1181286E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
MA26674A1 (fr) Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
AP9801174A0 (en) Cyclic sulfone derivatives.
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
BG106694A (en) Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
MA26738A1 (fr) Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3-carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ3048A1 (fr) Précurseurs médicamenteux mutuels d'amlopidine et d'atorvastine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26737A1 (fr) Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3-carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2392271A1 (fr) Sulfonylheteroaryltriazoles comme agents anti-inflammatoires/analgesiques